Structure Therapeutics' stock has declined ... also known as GSBR-1290, an oral small molecule selective glucagon-like-peptide-1 receptor (“GLP-1R”) agonist currently in two Phase 2 clinical ...

Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.